Please be aware: This activity must be completed in one session, please allow approximately 1 hour to complete.
If program is closed, you will need to restart the activity from the beginning.
Make sure you have a good internet connection.
Release Date: 01/25/2020 Expiration Date: 07/17/2021 (subject to change)
CE for this activity will not be available after this date.
Overview NP Dermatology specialists review recent guideline updates and incorporate new medication classes in this engaging infographic presentation. 1.0 CE and 1.0 RX. An estimated 18 million individuals in the U.S. have Atopic Dermatitis (AD), yet over 70% of patients report moderate to severe symptoms with ‘fair or poor’ overall health and significant impact of disease on quality of life. With new guidelines and new classes of drug therapies, NPs must be confident in their approach to diagnosis, treatment and patient education. AD is ranked the “most burdensome skin disorder” by the Global Burden of Disease Study with an estimated 18 million affected in the U.S. This includes 3% of adults and 20% of infants and children, and a financial burden of over $5 billion in 2015 with an additional near $30 billion in out-of-pocket expenses for adults alone.With new guidelines and new classes of drug therapies, NPs must be confident in their approach to diagnosis, treatment and patient education.
CE Credit Instructions
Read this activity description, including objectives and disclosures.
Review all additional materials provided (handouts, posttest reviews, any other downloadable resources).
After completing all content, go to Steps to Receive Credit:
Submit the evaluation to receive full AANP CE/Rx credit.
Objectives In this activity, designed for NPs practicing in Dermatology as well as rural and urban primary practice settings, the NP will learn to:
Recognize Atopic Dermatitis and classify severity according to most recent guidelines
Integrate a patient-centered, best-practice approach to educate patient/parent on AD disease management.
Select the best individualized treatment(s) based on classification of severity.
Faculty Margaret Bobonich, DNP, FNP-C, DCNP, FAANP Peggy Vernon, RN MA, CPNP, DCNP, FAANP Susan Tofte, BSN, MS, FNP-C Disclosure This activity was planned in accordance with AANP Accreditation Standards and Policies and is sponsored by an educational grant from Pfizer, Inc. Margaret Bobonich-Speakers Bureaus-psoriasis for AbbVie, Lilly, USA, Novartis, UCB Susan Tofte – Advisory Board, psoriasis for Celgene, Novartis and AD for Regeneron/Sanofi, Consultant AD for Pfizer Peggy Vernon-n/a Additional Information For questions about this online CE activity, or more information concerning the AANP CE Center, contact the AANP CE Center Manager at CECenter@aanp.org.
1 Contact Hour(s) of CE, All of which may be applied towards Pharmacology
Additional CE activities of interest
(OnDemand) What's New in Pediatric Pharmacology?
(OnDemand) Common Pediatric ENT Conditions: Current Evidence-Based Guidelines for Practice
(OnDemand) Pharmacology 101: New Drug Update
(OnDemand) Understanding Asthma-COPD Overlap
(OnDemand) Antimicrobial Therapy: Best Practice
(OnDemand) Advanced Hepatitis C Treatment: The NP’s Role in Eradicating the Disease in the Community
(OnDemand) 2019 Contraceptive Update
(OnDemand) Influenza Update and Review
(OnDemand) 12 Lead ECG Interpretation
(OnDemand) Marijuana: It's Approved, Now What?
(OnDemand) Antibiotics Infection and the Evidence: 2019 Update